ArticleOncogene2026
LINC-AC092535.5 regulates MICAL2 mRNA level to inhibit p53-mediated ferroptosis in nasopharyngeal carcinoma.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis is a form of iron-dependent programmed cell death (PCD) that, once activated, inhibits tumor progression. However, the specific mechanisms influencing ferroptosis in nasopharyngeal carcinoma (NPC) are limited and warrant further investigation. This study proposes that MICAL2 not only influences the nuclear translocation of p53 but also facilitates the ubiquitination of p53 by recruiting the E3 ubiquitination ligase MDM2, leading to its degradation. This process inhibits ferroptosis in NPC cells, thereby promoting NPC progression and adversely affecting the prognosis of NPC patients. Additionally, we identified a novel long non-coding RNA (lncRNA), LINC-AC092535.5, which directly modulates the MICAL2 mRNA level through dual reinforcement at both transcriptional and post-transcriptional levels. Transcriptome sequencing and RACE experiments provided insights into the function of this new lncRNA. These findings will contribute to the expansion of the ferroptosis gene regulatory network and inform new clinical treatment strategies for NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.